Chiu, Joanne Wing Yan http://orcid.org/0000-0002-8320-3166
Lee, Soo Chin http://orcid.org/0000-0002-5835-6419
Ho, James Chung-man http://orcid.org/0000-0003-4499-5284
Park, Yeon Hee http://orcid.org/0000-0003-4156-9212
Chao, Ta-Chung http://orcid.org/0000-0003-1451-1939
Kim, Sung-Bae http://orcid.org/0000-0001-5588-8332
Lim, Elgene http://orcid.org/0000-0001-8065-8838
Lin, Ching-Hung http://orcid.org/0000-0003-2403-4056
Loi, Sherene http://orcid.org/0000-0001-6137-9171
Low, Su Ying
Teo, Lynette Li San http://orcid.org/0000-0002-2817-9458
Yeo, Winnie http://orcid.org/0000-0002-0863-8469
Dent, Rebecca http://orcid.org/0000-0001-6421-7602
Funding for this research was provided by:
AstraZeneca (Daiichi Sankyo)
Article History
Accepted: 16 June 2023
First Online: 8 August 2023
Declarations
:
: AstraZeneca and Daiichi Sankyo provided funding to assist with the preparation of this article.
: Joanne Wing Yan Chiu received honorarium from AstraZeneca for consulting services and lectures related to the drug of interest; Soo Chin Lee received grants from Pfizer, Eisai, Taiho, ACT Genomics, Bayer, Karyopharm; consulting fees or honorarium from Pfizer, Novartis, AstraZeneca, ACT Genomics, Eli Lilly, MSD, Roche, Eisai; payments for lectures from Pfizer, Novartis, Astra Zeneca, ACT Genomics, MSD, Roche and Eisai; James Chung-man Ho received consulting fees or honorarium and lectures from AstraZeneca; Yeon Hee Park received grants AstraZeneca, Pfizer; consulting fees or honorarium from AstraZeneca, Pfizer, Lilly, MSD, Eisai, Roche, Daiichi Sankyo, MENARINI, Bixink, Everest and Novartis Pharmaceuticals; Payment for writing or review or reviewing manuscript for Lancet Oncology; and payment for lectures from AstraZeneca, Pfizer, Lilly, MSD, Eisai, Roche and Novartis Pharmaceuticals; Ta-Chung Chao has no conflicts of interest to disclose; Sung-Bae Kim received grants to their institution from Novartis, Sanofi-Aventis and DongKook Pharm Co; consulting fees or honorarium from Novartis, AstraZeneca, Lilly, Dae Hwa Pharmaceutical Co Ltd, ISU Abxis, OBI Pharma, Beigene and Daiichi Sankyo; and holds stock/stock options from Genopeaks and NeogeneTC; Elgene Lim received consulting fees or honorarium for advisory boards from AstraZeneca; provision of writing assistance (manuscript) by Medical Pharma Services; and payment for lectures by AstraZeneca; Ching-Hung Lin has no conflicts of interest to disclose; Sherene Loi receives research funding to her institution from Novartis, Bristol Myers Squibb, Merck, Puma Biotechnology, Eli Lilly, Nektar Therapeutics, AstraZeneca and Seattle Genetics. She has acted as consultant (not compensated) to Seattle Genetics, Novartis, Bristol Myers Squibb, Merck, AstraZeneca, Eli Lilly, Pfizer, Gilead Therapeutics and Roche-Genentech. She has acted as consultant (paid to her institution) to Aduro Biotech, Novartis, GlaxoSmithKline, Roche-Genentech, AstraZeneca, Silverback Therapeutics, G1 Therapeutics, PUMA Biotechnologies, Pfizer, Gilead Therapeutics, Seattle Genetics, Daiichi Sankyo, Merck, Amunix, Tallac Therapeutics, Eli Lilly and Bristol Myers Squibb; Sherene Loi is supported by the National Breast Cancer Foundation of Australia Endowed Chair and the Breast Cancer Research Foundation, New York; Su Ying Low received grants received from Boehringer Ingelheim; consulting fees or honorarium from Roche and Boehringer Ingelheim; payment for writing or reviewing manuscript from AstraZeneca; Lynette Teo consulting fees or honorarium and provision of writing assistance from AstraZeneca; Winnie Yeo consulting fees or honorarium from AstraZeneca and Daiichi Sankyo; payment for lectures from AstraZeneca and Daiichi Sankyo; Rebecca Dent has no conflicts of interest to disclose.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Conceptualisation and supervision: JWYC, RD; Writing—original draft preparation: all authors; Writing—review and editing: all authors. All authors read and approved the final manuscript.